A total of 40 patients with relapsed/refractory Hodgkin's disease (HD) underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) from an HLA-identical sibling (n ¼ 20) or a matched unrelated donor (n ¼ 20). The median age was 31 years (range 18-58). Disease status at allo-SCT was refractory relapse (n ¼ 14) or sensitive relapse (n ¼ 26). The conditioning regimens were fludarabine-cyclophosphamide7antithymocyte globulin (n ¼ 14), a less intensive regimen, and fludarabinemelphalan (FM) (n ¼ 26), a more intensive one. The two groups had similar prognostic factors. The median time to neutrophil recovery (ie absolute neutrophil count X500/ll) was 12 days (range 10-24). The median time to platelet recovery (ie platelet count X20 000/ll) was 17 days (range 7-132). Day 100 and cumulative (18-month) transplantrelated mortalities (TRMs) were 5 and 22%. Twenty-four patients (60%) are alive (14 in complete remission or complete remission, unconfirmed/uncertain) with a median follow-up of 13 months (4-78). In all, 16 patients expired (TRM n ¼ 8, disease progression n ¼ 8). FM patients had better overall survival (73 vs 39% at 18 months; P ¼ 0.03), and a trend towards better progression-free survival (37 vs 21% at 18 months; P ¼ 0.2). RIC allo-SCT is feasible in relapsed/refractory HD patients with a low TRM. The intensity of the preparative regimen affects survival. Bone Marrow Transplantation (2005) 35, 943-951.
allogeneic stem cell transplantation; bone marrow transplantation; peripheral blood stem cell transplantation Although many patients with Hodgkin's disease (HD) are successfully treated with chemotherapy and/or radiation therapy, the management of patients with relapsed or refractory disease remains a challenge. 1, 2 There is considerable experience with high-dose chemotherapy and autologous stem cell transplantation in these cases, with a sizable fraction of patients successfully salvaged and presumably cured. [3] [4] [5] Data on allogeneic stem cell transplantation (allo-SCT) in the management of relapsed or refractory HD are, on the other hand, more sketchy and far less encouraging. [6] [7] [8] Published reports of allo-SCT included a majority of patients who were extensively pretreated and/ or had advanced, chemoresistant disease. Despite high rates of transplant-related mortality (TRM) (50-60%), a subset of patients (15-18%) did achieve durable remissions.
The presence of a graft-versus-HD effect was postulated in some of these reports, 7, 8 raising the possibility that the outcome could be significantly more favorable in patients transplanted with less intensive preparative regimens and/ or earlier in the course of their disease. Recent data seem to support the existence of a graft-versus-HD, despite the persistence of a high TRM. 9 Allo-SCT following reduced-intensity conditioning (RIC) regimens is yielding very promising preliminary results in several hematological malignancies. 10, 11 Experience with RIC in HD is gradually accumulating. 12, 13 We elected to explore the feasibility of such an approach in patients with relapsed and refractory HD. Preliminary results of this study were reported previously 14 and are expanded upon here.
Patients and methods

Patients
All consecutive patients with relapsed or refractory HD who underwent allo-SCT during a 6-year period (8/1997-10/2003 ) at the MD Anderson Hospital (MDAH) following conditioning with one of two fludarabine-based preparative regimens (fludarabine-cyclophosphamide7antithymocyte globulin and fludarabine-melphalan (FM)) are included in this report. Patients were deemed eligible for allotransplantation if they had chemosensitive or stable disease (SD) after salvage chemotherapy, no active or uncontrolled infection as well as adequate cardiac, pulmonary, renal and hepatic function. Patients not meeting these criteria (eg progressive disease, poor organ function) were, however, also considered on a case-by-case, 'compassionate' basis (ie off protocol). Patients needed to have either an HLAidentical related donor or a fully serologically matched unrelated donor willing, and needed to be capable of donating filgrastim-mobilized peripheral blood progenitor cells (PBPCs: HLA-identical related donors) or bone marrow (matched unrelated donors).
The treatment plan for these patients was approved by the MDAH Surveillance Committee. All patients and donors were required to sign written informed consent. Unrelated donors were recruited, consented and harvested through the National Marrow Donor Program. All individual patient data presented in this report have been de-identified.
Conditioning regimens
The conditioning regimen in the first group of patients (n ¼ 14) consisted of fludarabine (25 mg/m 2 intravenously daily for 5 days), cyclophosphamide (1 g/m 2 intravenously daily for 3 days; FC: n ¼ 7) and, for matched unrelated donor transplants (as well as two sibling transplants in the initial phase of the study), antithymocyte globulin (ATG; 20 mg/kg intravenously daily for 3 days) (FC þ ATG: n ¼ 7). ATG was added to maximize engraftment. In view of the high early progression rate experienced in this initial cohort of patients, the conditioning regimen was changed in the successive 24 patients to a more intensive regimen, namely fludarabine (25 mg/m 2 intravenously daily for 5 days) and melphalan (70 mg/m 2 intravenously daily for 2 days) (FM), in order to provide more effective pretransplant cytoreduction. In two additional FM patients, the melphalan dose was 90 mg/m 2 intravenously daily for 2 days, either because treated on a compassionate basis (n ¼ 1) or because enrolled in a separate protocol (n ¼ 1).
Post-transplant immunosuppression
All patients received tacrolimus intravenously beginning 2 days before transplantation, dosed to maintain therapeutic serum levels (4-12 ng/ml) and switched to oral administration as soon as oral intake was feasible. In the absence of persistent or progressive disease, tacrolimus was ordinarily continued for a minimum of 6 months and subsequently tapered. Methotrexate (5 mg/m 2 intravenously) was administered on days 1, 3, 6 and (for the unrelated donor transplants) day 11 post transplant.
Criteria for study evaluation
Engraftment was defined as the first of three consecutive days of an absolute neutrophil count (ANC) X500/ml. Platelet recovery was considered to have occurred on the first of seven consecutive days of an unsupported platelet count X20 000/ml. Patients were evaluable for engraftment if they survived at least 30 days following their transplant and had a chimerism assay performed a minimum of 30 days after transplant. Chimerism was determined beginning at day 30-100 post-transplant on bone marrow or peripheral blood samples by restriction fragment length polymorphism (RFLP) or, more recently, with PCR-based microsatellite polymorphism analysis using established criteria. 15 Acute and chronic graft-versus-host disease was graded according to established criteria. 16, 17 Patients were considered evaluable for acute GVHD if they had achieved engraftment and for chronic GVHD if they had survived beyond day 100. TRM included all causes of death other than disease progression (PD) or relapse occurring at any time after transplant. Relapse-related mortality included all deaths in patients with active disease after transplant. However, in patients reinduced into remission (eg with salvage chemotherapy and/or donor leukocyte infusions (DLIs)) after PD or relapse, deaths were considered as transplant-related.
Response definitions
A complete remission (CR) was defined as the disappearance of all clinical and radiological evidence of active disease in all known sites for a minimum of four consecutive weeks. Complete remission, unconfirmed/ uncertain (CRU) was defined as the presence of residual radiographic abnormalities of unclear clinical significance, unchanged or decreased in size during an observation period of least 4 weeks and non-gallium-avid or negative on PET scan (if initially gallium-avid or positive on a PET scan).
CRU patients were considered as CRs after one full year without PD. Partial remission (PR) was defined as an at least 50% decrease in the sum of the products of diameters of any measurable lesion persisting for at least 4 weeks. SD was defined as any response not meeting PR criteria or lack of evidence of progressive disease. Progressive disease was defined as at least a 50% increase in measurable disease or the appearance of new disease sites. Early death was defined as death prior to day 100 after allo-SCT.
A sensitive relapse was defined as the achievement of at least a partial response to salvage chemotherapy, whereas failure to achieve at least a partial response qualified as refractory relapse. Both PD and relapse were considered as progressive disease (PD). Patients with evidence of PD and no active GVHD ordinarily had their immunosuppression tapered and/or withdrawn and were eligible, at the discretion of the investigator, to receive DLIs, with or without preceding salvage chemotherapy and /or radiation therapy. 18 
Statistical end points
In keeping with the pilot study design, the main end points were engraftment (ie neutrophil and platelet recovery as well as chimerism), and early (ie before day 100) TRM. Secondary end points were acute and chronic GVHD, cumulative TRM, PD or relapse, overall survival (OS) and progression-free survival (PFS). Actuarial rates of OS, PFS and acute GVHD were estimated by the method of Kaplan-Meier. 19 The cumulative incidence method was used to estimate the rates of TRM, PD and chronic GVHD. Death attributed to disease was considered a competing risk for TRM, and death in remission or without chronic GVHD was considered a competing risk for the later two events, respectively. Cox proportional hazards model 20 was used to evaluate outcomes according to type of conditioning regimen, stem cell source and response status pre-transplant. The effect of acute and/or chronic GVHD on PD was evaluated considering GVHD as a timedependent variable. Only univariate analysis was possible, given the small sample size. OS and PFS were measured in months from the day of transplantation until disease relapse or progression.
To minimize a potential selection bias in data reporting and make this report more clinically meaningful, all patients were included in the analysis, regardless of whether they were enrolled in the protocol.
Results
Patient characteristics
Characteristics of the 40 patients are displayed in Table 1 . The median age at transplant was 31 years (range 18-58). The median number of chemotherapy regimens received prior to allo-SCT was five (2) (3) (4) (5) (6) (7) (8) (9) . In all, 30 (75%) patients had received prior radiotherapy. A total of 30 (75%) had undergone a prior autologous stem cell transplant (auto-SCT), and the median time to progression after auto-SCT was 9 months (3-52).
Disease status at transplant was refractory relapse (n ¼ 14) and sensitive relapse (n ¼ 26). Eight patients (20%) were transplanted on a compassionate basis. All of 
Engraftment and GVHD
Hematological recovery data are presented in Table 2 . The median time to neutrophil recovery (ie ANC X500/ml) was 12 days (range 10-24). The median time to platelet recovery was 17 days (range 7-132). Chimerism data at day 30-100 indicate 100% donor-derived engraftment in 9/13 (69%) evaluable FC patients and 26/26 (100%) FM patients. One FC patient (patient 10) did not have chimerism studies performed at day 30-100, although peripheral blood studies done at day 20 revealed mixed chimerism (80% donor). Of the four FC patients with mixed chimerism, two had received sibling and two unrelated donor allografts. Two of these patients converted from mixed to full donor chimerism after DLIs. All of the long-term responders have ongoing 100% donor-derived engraftment, which has lasted a minimum of 6 months. The actuarial incidences of grade II-IV and grade III-IV acute GVHD were 38% (95% CI 25-55) and 10% (95% CI 4-25), respectively. The cumulative incidence of chronic ANC 500 ¼ first of three consecutive days of an absolute neutrophil count X500/ml; PLT 20K ¼ the first of seven consecutive days of an unsupported platelet count X20 000/ml. In eight FC patients the platelet count never dropped below 20 000/ml after the conditioning regimen, hence the figure '0'. a Patients transplanted on a compassionate (ie off protocol) basis.
GVHD at 18 months was 69% (SE 13%). There were no significant differences between the FC and FM groups in the incidence of grade II-IV acute GVHD (P-value ¼ 0.3), grade III-IV acute GVHD (P-value ¼ 0.55) or chronic GVHD (P-value ¼ 0.2).
Patient outcome: OS, PFS and PD
Median follow-up in the whole group was 12 months (range 2-78). OS, PFS (actuarial estimates) and PD (cumulative incidence) at 18 months were 61% (95% CI 42-76), 32% (95% CI 17-47) and 55% (s.e. 9%), respectively (Figures 1  and 2 ). At the time of the latest follow-up (March 2004), 24 patients (60%) are alive, with a median follow-up of 13 months (4-78). Of these, 14 patients are in CR or CRU. Three of them were reinduced into remission after initial PD (patients 16, 20 and 23). All three are alive and their median CR/CRU duration is 9 months (1-43). The median follow-up is 23 months (4-41) for the 11 patients alive and always in remission after allo-SCT.
Patient outcome: TRM and causes of death
Patient outcome data are presented in Table 3 . In all, 16 patients expired (40%). Of them, two died before day 100 (viral and bacterial pneumonia, respectively), accounting for a day 100 TRM of 5%. Also, 14 patients expired after day 100 (PD n ¼ 8, GVHD n ¼ 3, pulmonary nocardiosis n ¼ 1, intracranial hemorrhage n ¼ 1, diffuse alveolar hemorrhage n ¼ 1). Cumulative incidence of TRM at 18 months was 22% (s.e. 7%) (Figure 2 ).
Patient outcome according to conditioning regimen, stem cell source and response status pretransplant FC and FM patients were compared according to several known prognostic variables, as well as response status (ie chemosensitivity) pretransplant and stem cell source, and no statistically significant difference was observed between the two groups ( Figure 5 ). Progression rates were similar in the FM and FC patients (53%; s.e. 11 vs 57%; s.e. 14%, respectively, at 18 months, P ¼ 0.4). However, PD occurred later in FM patients (range 2-34 months) than in FC patients (range 0.7-13 months) ( Figure 6 ). In addition, with comparable follow-up time after progression, the FM group experienced a lower death rate after progression, although this did not reach statistical significance (3/12 progressors in the FM group vs 7/8 progressors in FC group; hazard ratio 0.3 and P ¼ 0.1). Cell source, chemosensitivity and the presence of B symptoms at transplant were evaluated as prognostic factors for OS, PD and PFS by univariate analysis. The effect of donor type was not evaluated separately as it was highly correlated with the stem cell source. None of these factors had a significant impact on outcome (data not shown).
Impact of acute and/or chronic GVHD on disease relapse/progression
The impact of GVHD (the earliest of acute or chronic) on PD was evaluated considering GVHD as time-dependent variable. There was a trend for lower relapse rate after the occurrence of GVHD; however, this was not statistically significant (hazard ratio 0.8; P ¼ 0.6). Similar results were obtained when acute GVHD grade 1 was not considered. All patients who had grade 2-4 acute GVHD survived up to at least day 100 post transplant.
Donor leukocyte infusions (DLIs)
Eight patients with PD received one (or more) DLIs, with (n ¼ 5) or without (n ¼ 3) preceding salvage chemotherapy and/or radiation therapy (Table 3 Mini-allogeneic transplant in Hodgkin's disease P Anderlini et al response (CRU) 9 months after his DLI. As all but one patient developed GVHD after the DLI, any correlation between GVHD and response could not be evaluated statistically. There was no obvious correlation between CD3 þ cell dose infused and disease response (data not shown). Our DLI experience in these patients has been reported in greater detail elsewhere. 18 
Discussion
The main purpose of this study was to explore in a singlecenter contest the feasibility of reduced-intensity, fludarabine-based conditioning for allografting from matched related and unrelated donors in advanced HD. The results proved that such approach is indeed feasible, with reliable engraftment rates (particularly in the FM patients) and a very low early (ie day 100) TRM (5% in this patient group as a whole). Cumulative TRM was also low at 22%, although this result will require a longer follow-up for proper evaluation. The feasibility of this approach extended to matched unrelated donor transplants.
The role of allo-stem cell transplantation in the management of relapsed/refractory HD remains controversial. Literature and registry data on mainly related donor transplants (Table 5 ) indicate virtually prohibitive early as well cumulative TRM and relapse rates (6) (7) (8) . Despite that, a subset of patients (15-18%) in these reports achieved long-term PFS. A more recent report, 9 while suggesting a somewhat more favorable long-term patient outcome (event-free survival 26% at 10 years), still listed a day 100 and overall TRM of 32 and 43%, respectively. Allo-SCT following a less intensive or even nonmyeloablative conditioning regimens is yielding very promising early results in several hematological malignancies, presumably due to its ability to harness a graft-versus-leukemia or lymphoma effect within the contest of a reduced transplantrelated toxicity. 10, 11 Heavily pretreated patients with relapsed and refractory HD may be ideal candidates for this approach, as their ability to tolerate conventional myeloablative preparative regimens is limited. In addition, thanks to its beneficial impact on early TRM, such approach may facilitate the detection of a graft-versus-HD effect.
Peggs et al presented an update of their experience on 41 patients (26 allografted from sibling donors, 15 from matched unrelated donors) conditioned with a FMalemtuzumab regimen. In all, 19 patients (46%) required DLIs, primarily for persistent or progressive disease. The cumulative TRM was 20% (11% DLI-related), with a projected 4-year PFS of 34%, not dissimilar from the one presented in this study. 12 Robinson et al 13 recently reported data on 90 HD patients who received an allograft (mainly from HLA-identical siblings) following a variety of preparative regimens (but primarily fludarabine-based conditioning), with an early (day 100) TRM of 11% with a 1-year PFS and OS of 45 and 60%, respectively. Burroughs et al have recently reported data with singledose total body irradiation (TBI)7fludarabine conditioning in 27 patients (18 allografted from sibling donors, nine from matched unrelated donors). Day 100 and 1-year nonrelapse mortality were 7 and 35%, respectively, but the 1-year PFS was only 18%. 21 A double transplantation approach (auto/allo) was also found to provide promising results, albeit in a smaller cohort of patients. The feasibility of reduced-intensity, fludarabine-based conditioning in matched unrelated donor allografts is particularly noteworthy, as inclusion of unrelated donor allografts would allow a far larger number of patients to potentially benefit from this strategy. Our results also suggested that, within the broad definition of 'reducedintensity' or 'nonmyeloablative', the intensity of the preparative regimen does affect patient outcome. Despite the limited sample size of this study, patients receiving FM had significantly better OS than patients receiving FC, a clearly less intensive regimen. PFS was superior as well, although the difference did not reach statistical significance, possibly because of the small sample size. We interpret these data as suggesting that, while the intensity may indeed be reduced, the preparative regimen still needs to have significant cytoreductive activity to impact patient outcome. This interpretation is also supported by a similar patient outcome reported by other investigators, 12, 13 with preparative regimens comparable to the one we employed. It is also consistent with the very poor 1-year PFS reported with low-dose TBI7fludarabine (ie a regimen with virtually no activity against HD).
21 Alternative explanations for these results do exist and include a possible deleterious effect of the ATG included in the FC regimen, unrecognized prognostic differences between the two groups, and improved supportive care modalities in the FM patients. However, all of these remain speculative. While the cumulative relapse rate per se was seemingly unaffected by the intensity of the preparative regimen, FM patients relapsed later and survived longer after PD.
With regard to the issue of a graft-versus-HD effect, in view of the very high TRM (as well as relapse rates) reported in the literature (Table 5) , it is hardly surprising that definitive proof of the very existence of a graft-versus-HD effect has largely eluded investigators, even if some have postulated it. Milpied et al 7 showed such an effect with Xgrade 2 acute GVHD. Anderson et al 8 reported a lower relapse rate in HD patients who received an allo-SCT when compared to recipients of an autologous SCT, and Akpek et al 9 showed a trend towards lower relapse rate in HD patients transplanted in chemosensitive relapse and patients who developed GVHD. These findings, as well as several case reports of disease responses following DLIs, 12, 23 support the existence of a graft-versus-HD effect. Our data do not allow a definitive conclusion on this issue. We evaluated the possible impact of GVHD (acute and/or chronic) on the development of disease relapse or progression. There was a trend for lower relapse rate after the occurrence of GVHD, although this did not reach statistical significance, possibly because of the sample size of the study. DLI data in these patients, although limited, are also suggestive of a graft-versus-HD effect, as discussed in greater detail elsewhere, 18 although definitive proof is still lacking.
The trend towards a higher TRM in the FC group (a less intensive regimen), while not reaching statistical significance, defies an immediate explanation. As discussed previously, this finding could be ascribed to the use of ATG in these patients and/or unrecognized prognostic differences increasing the risk of TRM in the FC group. While a formal comparison is not possible, it may be noteworthy to point out that HD patients conditioned with low-dose TBI7fludarabine (another minimally intensive regimen) also experienced a surprisingly high 1-year nonrelapse (ie transplant-related) mortality of 35%. 21 In conclusion, allo-stem cell transplantation with reduced-intensity, fludarabine-based conditioning is feasible in high-risk, heavily pretreated patients with relapsed and refractory HD, with very encouraging early TRM and engraftment rates. This approach seems well tolerated and deserves to be explored further in a larger number of patients, and ideally in patients with less advanced disease. While the short follow-up, small sample size, sequential nature of our study and patient heterogeneity all suggest some caution in data interpretation, we found that the intensity of the preparative regimen affects patient outcome. PD remains a major cause of treatment failure, and this will need to be addressed in the planning of future studies. Longer follow-up data will allow a more meaningful evaluation of the ultimate impact of this approach.
